Paper20535784
Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
Caporali R and 6 others. Arthritis Care Res (Hoboken), 2010. Cited by 96 papers, by iCite.
Cite this record
ConductScience Library. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Papers, record 20535784. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20535784
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Carrier State | Major topic |
| Hepatitis B Surface Antigens | Major topic |
| Hepatitis B virus | Major topic |
| Rheumatic Diseases | Major topic |
| Tumor Necrosis Factor-alpha | Major topic |
| Adult | |
| Aged | |
| Cohort Studies | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04356404 | Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients | Background |
Source ClinicalTrials.gov
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 96 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38734770 | Evaluation of risk for hepatitis B virus reactivation in patients with psoriasis treated with biologic therapies: a single-center retrospective study. | Arch Dermatol Res | 2024 | https://conductscience.org/library/papers/38734770 | PubMed |
| 37751983 | Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier. | BMJ Case Rep | 2023 | https://conductscience.org/library/papers/37751983 | PubMed |
| 36840482 | Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. | Immun Inflamm Dis | 2023 | https://conductscience.org/library/papers/36840482 | PubMed |
| 36744250 | Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/36744250 | PubMed |
| 36323488 | Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. | RMD Open | 2022 | https://conductscience.org/library/papers/36323488 | PubMed |
| 32897226 | Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection. | Turk J Gastroenterol | 2020 | https://conductscience.org/library/papers/32897226 | PubMed |
| 32206094 | Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. | Ther Adv Musculoskelet Dis | 2020 | https://conductscience.org/library/papers/32206094 | PubMed |
| 32098857 | Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. | RMD Open | 2020 | https://conductscience.org/library/papers/32098857 | PubMed |
| 29991894 | Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. | Ann Gastroenterol | 2018 | https://conductscience.org/library/papers/29991894 | PubMed |
| 29968197 | Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. | Clin Drug Investig | 2018 | https://conductscience.org/library/papers/29968197 | PubMed |
| 29694398 | Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections. | PLoS One | 2018 | https://conductscience.org/library/papers/29694398 | PubMed |
| 29164002 | Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series. | Eur J Rheumatol | 2017 | https://conductscience.org/library/papers/29164002 | PubMed |
| 29089055 | Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study. | Arthritis Res Ther | 2017 | https://conductscience.org/library/papers/29089055 | PubMed |
| 28834412 | Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. | Arthritis Care Res (Hoboken) | 2018 | https://conductscience.org/library/papers/28834412 | PubMed |
| 28090316 | The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. | Clin Transl Immunology | 2016 | https://conductscience.org/library/papers/28090316 | PubMed |
| 27605880 | Management of psoriasis patients with hepatitis B or hepatitis C virus infection. | World J Gastroenterol | 2016 | https://conductscience.org/library/papers/27605880 | PubMed |
| 26573663 | Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention. | Rheumatol Int | 2016 | https://conductscience.org/library/papers/26573663 | PubMed |
| 26420955 | Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/26420955 | PubMed |
| 26001631 | Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. | Arthritis Res Ther | 2015 | https://conductscience.org/library/papers/26001631 | PubMed |
| 25848463 | Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. | World J Hepatol | 2015 | https://conductscience.org/library/papers/25848463 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20535784
GET https://conductscience.org/api/papers/v1/20535784/cited_by?page=2